a study of enfortumab vedotin alone or with other therapies for treatment of urothelial cancer

Conditions: Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Urologic Neoplasms; Renal Pelvis Neoplasms; Urothelial Cancer; Ureteral Neoplasms; Urethral Neoplasms

Summary: this study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. pembrolizumab is an immune checkpoint inhibitor (cpi) that is used to treat patients with cancer of the urinary system (urothelial cancer). this type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. some parts of the study will look at locally advanced or metastatic urothelial cancer (la/muc), which means the cancer has spread to nearby tissues or to other areas of the body. other parts of the study will look at muscle-invasive bladder cancer (mibc), which is cancer at an earlier stage that has spread into the muscle wall of the bladder. this study will look at the side effects of enfortumab vedotin alone and with other anticancer therapies. a side effect is a response to a drug that is not part of the treatment effect. this study will also test if the cancer shrinks with the different treatment combinations.

this study will examine the safety and anticancer activity of enfortumab vedotin (ev) given intravenously as monotherapy and in combination with other anticancer therapies as first line (1l) and second line (2l) treatment for patients with urothelial cancer. the primary goal of the study is to determine the safety, tolerability, and efficacy of enfortumab vedotin alone and in combination with pembrolizumab and/or chemotherapy. the study will be conducted in multiple parts: locally advanced or metastatic urothelial cancer: * dose escalation * expansion * part 1: cohorts a and optional b * part 2: cohorts d, e, and optional f * part 3: cohort g. * randomized cohort k * ev monotherapy arm * ev combination arm muscle invasive bladder cancer: * cohort h * optional cohort j * cohort l

Eligibility criteria:
inclusion criteria: * locally advanced or metastatic urothelial cancer (la/muc) - cohorts a, b, d, e, f, g and k. * histologically documented la/muc, including squamous differentiation or mixed cell types. * an eastern cooperative oncology group (ecog) performance status score of 0, 1 or 2: participants with ecog performance status of 2 must meet the following additional criteria: hemoglobin ≥10 g/dl, gfr ≥50 ml/min, may not have nyha class iii heart failure. * eligible for pembrolizumab (dose-escalation cohorts, cohorts a, b, g and k combination arm). * dose-escalation cohorts: ineligible for first-line cisplatin-based chemotherapy and no prior treatment for la/muc, or have disease progression following at least 1 platinum-containing treatment. * cohort a: ineligible for cisplatin-based chemotherapy and no prior treatment for la/muc. no prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months. * cohort b: must have disease progression during/following treatment with at least 1 platinum-containing regimen for la/muc or disease recurrence. * cohort d: eligible for cisplatin-based chemotherapy and no prior treatment for la/muc. no prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months. * cohort e: ineligible for cisplatin-based chemotherapy, eligible for carboplatin, and no prior treatment for la/muc. no prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months. * cohort f: ineligible for platinum-based chemotherapy, or disease progression during/following at least 1 prior treatment for la/muc. eligible for gemcitabine. * cohort g: eligible for platinum-based chemotherapy (either cisplatin or carboplatin) and no prior treatment for la/muc. no prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months. * cohort k: ineligible for cisplatin-based chemotherapy due to at least 1 of the following: glomerular filtration rate (gfr) \<60 ml/min and ≥30 ml/min, ecog performance status of 2, nci ctcae version 4.03 grade ≥2 hearing loss, new york heart association (nyha) class iii heart failure. no prior systemic treatment for locally advanced or metastatic disease. no adjuvant/neoadjuvant platinum-based therapy within 12 months prior to randomization. * muscle invasive bladder cancer (mibc)- cohorts h, j and l. * histologically confirmed mibc with predominant \>50% urothelial histology: cohorts h and j: clinical stage ct2-t4an0m0; cohort l: clinical stage ct2-t4an0m0 or ct1-t4an1m0: participants with pt1 disease are eligible only if they have n1 disease on imaging. mixed cell types are eligible if urothelial cancer is predominant (\>50%); participants with plasmacytoid and/or neuroendocrine tumors are ineligible regardless of component percentage. urothelial tumors not originating in the bladder (eg, upper tract tumors, urethral tumors) are ineligible. * must be cisplatin-ineligible. * cohort-specific eligibility: cohort j, h, and l: no prior systemic treatment, chemoradiation, or radiation therapy for mibc. may have received prior intravesical bacillus calmette-guerin (bcg) or intravesical chemotherapy for non-mibc; cohort j: eligible for pembrolizumab. * ecog performance status of 0, 1, or 2. * anticipated life expectancy of ≥3 months. * tumor samples with an associated pathology report from the diagnostic transurethral resection of a bladder tumor done 90 days prior to the first dose of study treatment must be available prior to enrollment and determined to be sufficient for pathology review and biomarker analysis. * participants must be deemed eligible for rc+plnd. exclusion criteria: * la/muc - cohorts a, b, d, e, f, g, and k * received any prior treatment with a pd-1 inhibitor, pd-l1 inhibitor, or pd-l2 inhibitor, except cohort f. * received any prior treatment with stimulatory or co-inhibitory t-cell receptor agents, such as cd137 agonists, ox-40 agonists, or cytotoxic t-lymphocyte-associated protein 4 (ctla-4) inhibitors (except cohort f). * ongoing sensory or motor neuropathy grade 2 or higher. * active central nervous system (cns) metastases. * ongoing clinically significant toxicity (grade 2 or greater) associated with prior treatment (including radiotherapy or surgery). * conditions requiring high doses of steroids or other immunosuppressive medications. * prior treatment with enfortumab vedotin or other monomethyl auristatin e (mmae)-based antibody-drug conjugates (adcs). * uncontrolled diabetes mellitus. * mibc - cohorts h, j, and l * received prior systemic treatment, chemoradiation, and/or radiation therapy of muscle invasive bladder cancer. * received any prior treatment with a cpi. * received any prior treatment with stimulatory or co-inhibitory t-cell receptor agents, such as cd137 agonists, ctla-4 inhibitors, or ox-40 agonists. * for participants in cohort h, evidence of nodal disease on imaging. for participants in cohort l, ≥n2 nodal disease on imaging. * participant has undergone partial cystectomy of the bladder to remove any nmibc or mibc. * ongoing sensory or motor neuropathy grade 2 or higher. * conditions requiring high doses of steroids or other immunosuppressive medications. * prior treatment with enfortumab vedotin or other mmae-based adcs for urothelial cancer. * participants with a history of another invasive malignancy within 3 years before first dose of study drug.

Keywords: asg-22me asg-22ce antibody-drug conjugate antineoplastic agents cpi enfortumab vedotin mibc locally advanced urothelial cancer cisplatin drug therapy carboplatin metastatic urothelial cancer nectin-4 gemcitabine muscle invasive bladder cancer checkpoint inhibitors pembrolizumab pd-1 inhibitor